SS-31, also called elamipretide, is a synthetic peptide that binds to the inner membrane of mitochondria and protects them from damage. It has been studied in clinical trials for heart failure and age-related mitochondrial decline.

MOTS-c vs SS-31: Which Mitochondrial Peptide Fits You?

Built by medical professionals, gym rats, and experienced biohackers

MOTS-c is for metabolism and exercise. SS-31 is for heart and mitochondrial protection. Both target the cell's energy factories (mitochondria), but they work through completely different routes.

Quick Answer
MOTS-c is a naturally occurring peptide, made inside your own mitochondria, studied for metabolic health and exercise capacity. SS-31 (elamipretide) is a synthetic peptide that attaches to the inner wall of mitochondria and shields them from damage. People focused on metabolic function and fitness lean toward MOTS-c. People focused on heart health or age-related mitochondrial decline lean toward SS-31. SS-31 has more human clinical trial data than MOTS-c.

What Is MOTS-c?

MOTS-c is a short peptide (a chain of amino acids) that your body produces inside mitochondria. Researchers discovered it in 2015 .

It works through a pathway called AMPK. AMPK is a built-in sensor that tells cells how to manage energy. When AMPK is active, cells burn fat more efficiently and become more sensitive to insulin.

Animal studies suggest MOTS-c may improve insulin sensitivity and support metabolic health . It also appears to boost fat burning during exercise. Human data is early-stage and very limited.

What Is SS-31?

SS-31 is also known as elamipretide. It is a synthetic four-amino-acid peptide that was designed specifically to target mitochondria.

It binds to a fat molecule called cardiolipin on the inner membrane (the innermost layer) of mitochondria. By anchoring there, it stabilizes the membrane. It also reduces damage from harmful molecules called reactive oxygen species (ROS).

SS-31 has been tested in human clinical trials for heart failure and age-related mitochondrial decline . That gives it a stronger human evidence base than most research peptides.

How Do MOTS-c and SS-31 Differ?

How does each one work?

MOTS-c activates the AMPK energy-sensing pathway. This tells cells to use energy more efficiently, especially during exercise or metabolic stress.

SS-31 physically protects the inner membrane of mitochondria from damage. It does not change how energy is sensed; it protects the structure itself.

These are different mechanisms aimed at different problems.

What do people use each one for?

MOTS-c is discussed for metabolic health, fat loss support, insulin sensitivity, and exercise performance.

SS-31 is discussed for heart protection, age-related mitochondrial damage, and conditions tied to declining mitochondrial function.

What are the typical research doses?

MOTS-c is typically studied at 5 to 10 mg per week in animal models . A clear human dose has not been established.

SS-31 doses in human trials have ranged from 2 to 10 mg per day . The exact dose varies by protocol.

How fast do effects appear?

Both are slow-acting compounds. People report noticing changes over weeks rather than days.

How strong is the evidence?

This is where they clearly diverge. SS-31 has completed phase I and phase II human clinical trials . MOTS-c has mostly animal and cell research, with very little human data.

Side-by-Side Comparison

Feature	MOTS-c	SS-31 (Elamipretide)
Type	Mitochondria-derived peptide	Synthetic tetrapeptide
Main target	AMPK energy-sensing pathway	Cardiolipin on inner mitochondrial membrane
Primary use discussed	Metabolic health, exercise, fat use	Heart protection, age-related mitochondrial decline
Research dose	5 to 10 mg/week (animal data) [verify]	2 to 10 mg/day (human trials) [verify]
Onset	Weeks to months	Weeks (some effects studied acutely)
Human evidence	Very limited	Stronger; multiple clinical trials
How it is given	Subcutaneous injection	Subcutaneous injection

Can You Stack MOTS-c and SS-31?

These two peptides target different parts of the mitochondrial system. MOTS-c works on energy signaling at the cellular level, while SS-31 protects the inner membrane from structural damage.

Because they hit different targets, some researchers consider them potentially complementary . No published human stacking studies exist for this combination. This is general community reasoning, not personalized medical advice. Always talk to a licensed clinician before combining any compounds.

Which Do People Pick, and When?

This is general guidance only, not personalized advice. Consult a licensed clinician before starting any peptide protocol.

People tend to choose MOTS-c when:
- Metabolic health or insulin sensitivity is the main goal
- They want a peptide with exercise-performance data in animal studies
- They are interested in energy metabolism and fat use

People tend to choose SS-31 when:
- Heart health or cardiovascular protection is the main concern
- Age-related mitochondrial decline is the focus
- They want a compound with more human clinical trial data behind it

Some people consider both when:
- They want to address both mitochondrial energy signaling and structural protection
- They are running a broader longevity-focused stack

Running more than one peptide across different cycles takes real organization. DoseVault lets you log each compound and track how you feel week to week. Keep your whole protocol in one place.

Frequently Asked Questions

What is MOTS-c?

MOTS-c is a peptide your body makes inside mitochondria. Animal studies link it to improved insulin sensitivity, better fat metabolism, and increased exercise capacity. Human trial data is very limited.

What is SS-31?

SS-31 (elamipretide) is a synthetic peptide that binds to the inner mitochondrial membrane. It protects that membrane from damage. It has been studied in clinical trials for heart failure and age-related mitochondrial decline.

Can you stack MOTS-c and SS-31?

Some researchers consider them potentially complementary because they target different parts of mitochondria. MOTS-c works through an energy-sensing pathway, while SS-31 protects the inner membrane. No published stacking studies exist. This is general guidance, not personalized medical advice.

Which has more human evidence, MOTS-c or SS-31?

SS-31 has more human data. It has been studied in clinical trials for heart failure and aging-related conditions. MOTS-c has mostly animal and lab-based research, with very limited human trial data.

Disclaimer

This article is for educational purposes only and is not medical advice. MOTS-c and SS-31 are not approved by the FDA for general use. Do not use any compound to diagnose, treat, cure, or prevent any condition. Always consult a licensed clinician before starting any peptide protocol.

Built by medical professionals, gym rats, and experienced biohackers

Ready to track your peptide protocol? DoseVault helps you log doses, set reminders, and monitor how you feel across every cycle, all in one place.